SNG.L

Synairgen Plc
Synairgen plc - Results of AGM and Appointment of New Chairman
10th October 2024, 16:05
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7696H
Synairgen plc
10 October 2024
 

 


Synairgen plc

('Synairgen' or the 'Company')

Results of Annual General Meeting and Appointment of New Chairman

 


Southampton, UK - 10 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Meeting today. All resolutions proposed at its Annual General Meeting were passed.

The full results of the proxy voting and text of the resolutions can be viewed by visiting the Company's website at www.synairgen.com/investors/aim-rule-26.

Following the announcement on 18 September, Dr. Mark Parry-Billings has now succeeded Simon Shaw as Chairman of the Board of Directors, effective immediately post today's AGM. Dr. Parry-Billings is an accomplished international biotech and pharmaceutical executive with a successful track record of more than 30 years heading R&D and leading businesses. Most recently, he served as Global Head of Drug Development at Chiesi. Prior to this, he served as CEO of Topigen Pharmaceuticals until its acquisition by Pharmaxis in 2010. Mark has deep expertise in respiratory therapeutics and drug delivery to the lungs, notably having led multiple novel respiratory assets from early stage through clinical development and to market approvals, with a primary focus on inhaled drug delivery. 

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

 

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Nigel Birks - Life Science Specialist Sales

 

Tel: + 44 (0) 20 7220 0500

 

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

 

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEAKEEFEALFFA]]>
TwitterFacebookLinkedIn